Median Technologies’ eyonis® LCS Obtains CE Marking
European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe
Regulatory News:
